Polivy Disease Interactions

The use of polatuzumab vedotin can cause serious or severe myelosuppression including neutropenia, thrombocytopenia, and anemia. Cytopenias may require a delay, dose reduction, or discontinuation of polatuzumab vedotin. It is recommended to monitor complete blood counts during treatment. Consider prophylactic granulocyte colony stimulating factor administration if needed.

No adjustment in the starting dose of polatuzumab vedotin is required in patients with mild hepatic impairment. The use of polatuzumab vedotin in patients with moderate or severe hepatic impairment should be avoided. Serious cases of hepatotoxicity that were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, have occurred in patients treated with polatuzumab vedotin. This agent has not been studied in patients with moderate or severe hepatic impairment. Patients with moderate or severe hepatic impairment are likely to have increased exposure to the MMAE component, which may increase the risk of adverse reactions. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk of hepatotoxicity. Monitor liver enzymes and bilirubin level as appropriate.

Fatal and/or serious infections, including opportunistic infections such as sepsis, pneumonia (including Pneumocystis jiroveci and other fungal pneumonia), herpesvirus infection, and cytomegalovirus infection have occurred in patients treated with polatuzumab vedotin. Hold polatuzumab vedotin and any concomitant chemotherapy if progressive multifocal leukoencephalopathy (PML) is suspected, and permanently discontinue if the diagnosis is confirmed. Closely monitor patients during treatment for signs of infection. It is recommended to administer prophylaxis for Pneumocystis jiroveci pneumonia and herpesvirus.

Polatuzumab vedotin can cause peripheral neuropathy, including severe cases. Care should be exercised when using this agent in patients with preexisting peripheral neuropathy as it may exacerbate the condition. It is recommended to monitor for symptoms of peripheral neuropathy and if experiencing new or worsening peripheral neuropathy patients may require a delay, dose reduction, or discontinuation of treatment.

The use of polatuzumab vedotin may cause tumor lysis syndrome. Patients with high tumor burden and rapidly proliferative tumor may be at increased risk of tumor lysis syndrome. It is recommended to closely monitor for signs of tumor lysis syndrome and to take appropriate measures, including tumor lysis syndrome prophylaxis as appropriate.